Figure 3.
Early BAL and plasma antibody features predict Mtb control at necropsy
(A and D) Spearman correlations between total Mtb CFU measured at necropsy and each (A) BAL and (D) plasma antibody measurement collected at peak immunogenicity (week 4). Antibody features with low signal (average fold change less than 1.25) were removed prior to correlation analysis. Black dotted horizontal line indicates an unadjusted p value of 0.05. Red and blue dots represent antibody features with a significant positive or negative correlation with total Mtb CFU, respectively, following multiple testing correction (Benjamini-Hochberg adjusted p value <0.05).7
(B and E) PLS-DA model fit using LASSO-selected antibody features in the (B) BAL and (E) plasma. Left: plot of latent variable (LV) 1 and 2. Ellipses represent 95-percentile normal level sets. Right: LV1 loadings.
(C and F) Area under the receiver operating characteristic curve (AUROC) analysis using individual antibody features in the (C) BAL and (F) plasma. Left: AUROC of the five most predictive features. Top individual antibody predictor in black, remaining features in gray. Right: receiver operating characteristic plot of the top individual antibody predictor in the (C) BAL and (F) plasma. 95% confidence intervals of the AUROC are shown in brackets.